Effect of hyperthermic intraperitoneal chemotherapy on intestinal flora and immune function in patients after radical distal gastrectomy for gastric cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049672

Enrollment

Unknown

Registered

2021-08-08

Start date

2021-08-09

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Experimental group:hyperthermic intraperitoneal chemotherapy

Control group:none

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Able to complete laparoscopic distal gastrectomy for gastric cancer; 2. Preoperative pathological diagnosis of gastric cancer; 3. The patient's general condition is good, and there is no serious heart, lung, kidney, liver dysfunction or metabolic disease; 4. No serious obstruction, perforation and bleeding occurred before surgery; 5. No distant metastatic lesions were found before surgery; 6. Have not received radiotherapy or chemotherapy; 7. Informed and voluntarily participated in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Abdominal and pelvic ultrasound or CT and chest X-ray examinations suggest that there is distant metastasis (M1); 2. Those who cannot tolerate surgery due to the function of vital organs; 3. Patients receiving other clinical trials at the same time; 4. The research cannot be completed on time as determined by the investigator.

Design outcomes

Primary

Measure	Time frame
Intestinal flora;Humoral immune function;Cellular immune function;	—

Countries

China

Contacts

Public ContactZhang Huanhu

Weihai Municipal Hospital

18660377179@163.com+86 18660377179

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026